201 related articles for article (PubMed ID: 25510278)
21. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
22. High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia.
Steeghs EMP; Bakker M; Hoogkamer AQ; Boer JM; Hartman QJ; Stalpers F; Escherich G; de Haas V; de Groot-Kruseman HA; Pieters R; den Boer ML
Sci Rep; 2018 Jan; 8(1):693. PubMed ID: 29330417
[TBL] [Abstract][Full Text] [Related]
23. ERG and c-MYC regulate a critical gene network in BCR::ABL1-driven B cell acute lymphoblastic leukemia.
Behrens K; Brajanovski N; Xu Z; Viney EM; DiRago L; Hediyeh-Zadeh S; Davis MJ; Pearson RB; Sanij E; Alexander WS; Ng AP
Sci Adv; 2024 Mar; 10(10):eadj8803. PubMed ID: 38457494
[TBL] [Abstract][Full Text] [Related]
24. Science Signaling Podcast for 29 November 2016: Pre-B cell receptor signaling in leukemia.
Wilson BS; VanHook AM
Sci Signal; 2016 Nov; 9(456):c23. PubMed ID: 27899524
[TBL] [Abstract][Full Text] [Related]
25. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
Tharkar-Promod S; Johnson DP; Bennett SE; Dennis EM; Banowsky BG; Jones SS; Shearstone JR; Quayle SN; Min C; Jarpe M; Mosbruger T; Pomicter AD; Miles RR; Chen WY; Bhalla KN; Zweidler-McKay PA; Shrieve DC; Deininger MW; Chandrasekharan MB; Bhaskara S
Leukemia; 2018 Jan; 32(1):49-60. PubMed ID: 28579617
[TBL] [Abstract][Full Text] [Related]
26. The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and Clinical Outcome in Acute Lymphoblastic Leukemia.
Chen D; Zheng J; Gerasimcik N; Lagerstedt K; Sjögren H; Abrahamsson J; Fogelstrand L; Mårtensson IL
PLoS One; 2016; 11(9):e0162638. PubMed ID: 27611867
[TBL] [Abstract][Full Text] [Related]
27. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
[TBL] [Abstract][Full Text] [Related]
28. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
[TBL] [Abstract][Full Text] [Related]
29. Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia.
Gillis LC; Berry DM; Minden MD; McGlade CJ; Barber DL
Leukemia; 2013 Aug; 27(8):1666-76. PubMed ID: 23399893
[TBL] [Abstract][Full Text] [Related]
30. STAT5 in B cell development and leukemia.
Malin S; McManus S; Busslinger M
Curr Opin Immunol; 2010 Apr; 22(2):168-76. PubMed ID: 20227268
[TBL] [Abstract][Full Text] [Related]
31. Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Abdelrasoul H; Vadakumchery A; Werner M; Lenk L; Khadour A; Young M; El Ayoubi O; Vogiatzi F; Krämer M; Schmid V; Chen Z; Yousafzai Y; Cario G; Schrappe M; Müschen M; Halsey C; Mulaw MA; Schewe DM; Hobeika E; Alsadeq A; Jumaa H
Nat Commun; 2020 Jun; 11(1):3194. PubMed ID: 32581241
[TBL] [Abstract][Full Text] [Related]
32. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.
Köhrer S; Havranek O; Seyfried F; Hurtz C; Coffey GP; Kim E; Ten Hacken E; Jäger U; Vanura K; O'Brien S; Thomas DA; Kantarjian H; Ghosh D; Wang Z; Zhang M; Ma W; Jumaa H; Debatin KM; Müschen M; Meyer LH; Davis RE; Burger JA
Leukemia; 2016 Jun; 30(6):1246-54. PubMed ID: 26847027
[TBL] [Abstract][Full Text] [Related]
33. SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia.
Brown LM; Hediyeh-Zadeh S; Sadras T; Huckstep H; Sandow JJ; Bartolo RC; Kosasih HJ; Davidson NM; Schmidt B; Bjelosevic S; Johnstone R; Webb AI; Khaw SL; Oshlack A; Davis MJ; Ekert PG
Blood Adv; 2022 Apr; 6(7):2373-2387. PubMed ID: 35061886
[TBL] [Abstract][Full Text] [Related]
34. Broad feedback inhibition of pre-B-cell receptor signaling components.
Hauser J; Verma-Gaur J; Grundström T
Mol Immunol; 2013 Jul; 54(3-4):247-53. PubMed ID: 23318223
[TBL] [Abstract][Full Text] [Related]
35. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
36. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
Okabe S; Tauchi T; Ohyashiki K
Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
[TBL] [Abstract][Full Text] [Related]
37. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia.
Gruber TA; Chang MS; Sposto R; Müschen M
Cancer Res; 2010 Oct; 70(19):7411-20. PubMed ID: 20876806
[TBL] [Abstract][Full Text] [Related]
38. RAG-mediated DNA double-strand breaks activate a cell type-specific checkpoint to inhibit pre-B cell receptor signals.
Bednarski JJ; Pandey R; Schulte E; White LS; Chen BR; Sandoval GJ; Kohyama M; Haldar M; Nickless A; Trott A; Cheng G; Murphy KM; Bassing CH; Payton JE; Sleckman BP
J Exp Med; 2016 Feb; 213(2):209-23. PubMed ID: 26834154
[TBL] [Abstract][Full Text] [Related]
39. Interference of BCR-ABL1 kinase activity with antigen receptor signaling in B cell precursor leukemia cells.
Klein F; Feldhahn N; Müschen M
Cell Cycle; 2004 Jul; 3(7):858-60. PubMed ID: 15254401
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
